Yueh-Fen Li

Yueh-Fen Li

Auto-generated profile, based on publicly available information

Yueh-Fen Li

Department of Microbiology, The Ohio State University, Columbus, OH 43210, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2018 in Antibiotics
Verified
Journal Article
Open access
PDF file
CHCristina Howard-Varona
Cristina Howard-Varona
DVDean R. Vik
Dean R. Vik
NSNatalie E. Solonenko
Natalie E. Solonenko
YLYueh-Fen Li
Yueh-Fen Li
MGM. Consuelo Gazitua
M. Consuelo Gazitua
MSMatthew B Sullivan
Matthew B Sullivan
Hemolytic–uremic syndrome is a life-threating disease most often associated with Shiga toxin-producing microorganisms like Escherichia coli (STEC), including E. coli O157:H7. Shiga toxin is encoded by resident prophages present within this bacterium, and both its production and release depend on the induction of Shiga toxin-encoding prophages. Consequently, treatment of STEC infections tend to be largely supportive rather than antibacterial, in part due to concerns about exacerbating such prophage induction. Here we explore STEC O157:H7 prophage induction in vitro as it pertains to phage therapy—the application of bacteriophages as antibacterial agents to treat bacterial infections—to curtail prophage induction events, while also reducing STEC O157:H7 presence. We observed that cultures treated with strictly lytic phages, despite being lysed, produce substantially fewer Shiga toxin-encoding temperate-phage virions than untreated STEC controls. We therefore suggest that phage therapy could have utility as a prophylactic treatment of individuals suspected of having been recently exposed to STEC, especially if prophage induction and by extension Shiga toxin production is not exacerbated.